AGIO - Agios Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
51.51
-0.50 (-0.96%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close52.01
Open52.58
Bid44.00 x 800
Ask54.98 x 900
Day's Range51.35 - 52.98
52 Week Range28.36 - 68.94
Volume534,602
Avg. Volume772,557
Market Cap3.522B
Beta (5Y Monthly)2.55
PE Ratio (TTM)N/A
EPS (TTM)-6.86
Earnings DateApr 29, 2020 - May 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.70
  • Agios' (AGIO) Q4 Loss Narrower Than Expected, Revenues Beat
    Zacks

    Agios' (AGIO) Q4 Loss Narrower Than Expected, Revenues Beat

    Agios (AGIO) rides high on earnings and revenue beat in the fourth quarter of 2019.

  • Thomson Reuters StreetEvents

    Edited Transcript of AGIO earnings conference call or presentation 13-Feb-20 1:00pm GMT

    Q4 2019 Agios Pharmaceuticals Inc Earnings Call

  • Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
    Zacks

    Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates

    Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 10.11% and 13.97%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Agios Reports Fourth Quarter and Full Year 2019 Financial Results

    – Fourth Quarter TIBSOVO® Net Revenue of $19.6M and $59.9M for Full Year 2019; Full Year 2020 U.S. TIBSOVO® Net Revenue Expected to be Between $105-115 Million – – New Clinical.

  • GlobeNewswire

    Agios to Present at the Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020

    CAMBRIDGE, Mass., Feb. 11, 2020 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.

  • Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?
    Zacks

    Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?

    Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • If You Had Bought Agios Pharmaceuticals (NASDAQ:AGIO) Stock Five Years Ago, You'd Be Sitting On A 57% Loss, Today
    Simply Wall St.

    If You Had Bought Agios Pharmaceuticals (NASDAQ:AGIO) Stock Five Years Ago, You'd Be Sitting On A 57% Loss, Today

    It is doubtless a positive to see that the Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) share price has gained some 48...

  • GlobeNewswire

    Agios to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020

    CAMBRIDGE, Mass., Jan. 30, 2020 -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.

  • Analysts: 3 Healthcare Stocks That Could Gain 35% — Or More
    TipRanks

    Analysts: 3 Healthcare Stocks That Could Gain 35% — Or More

    Returns, that’s the name of the investing game. At the end of the day, investors are after the names that can help them generate a profit in the stock market. It’s as simple as that. The hard part, though, is determining which investment opportunities have the best chance of outperforming the market in the years to come.As not all stocks are created equal, Wall Street pros suggest doing some due diligence. This includes a close reading of what the analyst community has to say about the long-term growth prospects of a potential portfolio addition.Bearing this in mind, we applied this strategy to our own search for compelling investments in the healthcare space. With TipRanks’ Stock Screener tool, we used the sector, analyst consensus rating and price target upside filters to scan the market for the crème-de-la-crème. As a result, we pinpointed 3 buy-rated healthcare names that have received substantial support from Wall Street analysts. One more thing – each boasts over 30% upside potential from current levels. Let’s jump right in.GW Pharmaceuticals (GWPH) GW Pharmaceuticals leads the way when it comes to plant-derived cannabinoid therapeutics. It developed Epidiolex, the first cannabis plant-derived medicine to be approved by the FDA, which can be used for seizures associated with drug-resistant forms of epilepsy, Lennox-Gastaut Syndrome and Dravet Syndrome. While it has certainly struggled over the last six months, the Street is behind GWPH.On Monday, the company announced that Epidiolex revenue for the fourth quarter came in at $104 million, surpassing the $99 million consensus estimate. Not to mention this figure reflects an 18% quarter-over-quarter increase. While acknowledging that investors had expressed some doubts about the drug’s growth prospects, Cowen analyst Phil Nadeau argues that this performance should put these fears to bed.Adding to the good news, the five-star analyst believes that Epidiolex approval for tuberous sclerosis complex (TSC) is very likely. Importantly, this approval would expand its “penetration of the broader refractory epilepsy population.” As the CDC estimates there are 3.4 million people with active epilepsy in the U.S., with approximately one-third having seizures despite current regimens, the market opportunity is huge.An approval for TSC indication could also increase the average per patient dose of Epidiolex and allow for greater uptake among focal seizure patients. “These results may widen Epidiolex's dosing range by allowing physicians additional dosing flexibility for those patients who need it. The TSC data also establishes the efficacy of Epidiolex in focal seizures,” Nadeau noted.All of the above caused the analyst to conclude that the full value of the drug hasn’t been built into the share price. As a result, Nadeau reiterated an Outperform rating and $200 price target. Should the target be met, shares will be in for a 69% twelve-month gain. (To watch Nadeau’s track record, click here)What does the rest of the Street think? It turns out that they wholeheartedly agree with Nadeau. With 12 Buy ratings and no Holds or Sells, the message is clear: GWPH is a Strong Buy. If that wasn’t enough, the $200.70 average price target puts the upside potential at 69.5%. (See GW Pharmaceuticals stock analysis on TipRanks)Agios Pharmaceuticals (AGIO)Using its expertise in cellular metabolism and precision medicine, Agios Pharmaceuticals has developed a product pipeline to fight cancer and other rare genetic diseases. After it shared its vision for the company in the next five years, one analyst sees AGIO’s growth story as just getting started.Needham’s Chad Messer tells investors that management’s TIBSOVO guidance is encouraging. Expecting an increase in uptake for both the relapsed and frontline settings, the company predicts that full year 2020 sales could land within the range of $105 million to $115 million, an 80% year-over-year growth rate if achieved.With the drug currently being evaluated for further label expansion from frontline combinations in acute myeloid leukemia (AML) and approvals in myelodysplastic syndromes (MDS) and cholangiocarcinoma (CCA), the analyst thinks that TIBSOVO will be able to capture most AML patients with an IDH1 mutation in the next few years.Additionally, AGIO initiated two expansion cohorts in combination with taxanes in non-small-cell lung carcinoma (NSCLC) and pancreatic cancer in its third quarter and top-line data from both mitapivat pivotal studies should be released in 2020. “Mitapivat could be approved in adults with PKD by 2021, and in pediatric patients by 2024. Agios will also present data from the Phase II thalassemia study and provide details on a pivotal program in 2020. A Go/No-Go decision is expected for mitapivat in sickle cell anemia later this year. AG-946, a mitapivat follow-on, will enter the clinic in 2020,” Messer noted.Based on everything that the healthcare company has going for it, Messer decided to stay with the bulls, maintaining the Buy recommendation. The five-star analyst’s $71 price target implies upside potential of 35%. (To watch Messer’s track record, click here)Looking at the consensus breakdown, other analysts generally take a similar approach when it comes to AGIO. 8 Buys and 1 Hold assigned in the last three months add up to a Strong Buy consensus rating. A potential twelve-month climb of 24% could be in the cards given the $62.43 average price target. (See Agios stock analysis on TipRanks)Daré Bioscience (DARE)Following its 100% rise this week, the talk on Wall Street has shifted to Daré Bioscience. The massive gain came after the company, which develops novel therapies to improve the treatment options in women’s health, broke the news of its exclusive licensing agreement with Bayer for U.S. commercial rights to its non-hormonal, one-monthly vaginal contraceptive, Ovaprene.As part of the agreement, Daré will receive an undisclosed upfront payment, which could be up to $310 million in commercial milestones and tiered double-digit royalties. After a pivotal study is conducted, Bayer can obtain exclusive rights to commercialize Ovaprene in the U.S. If Bayer ultimately decides to make the $20 million opt-in, this will cause the exclusive license to go into effect.Maxim analyst Jason McCarthy argues that as Bayer will most likely make the $20 million payment, this deal reflects the large potential for Ovaprene. “Bayer sees the value in Ovaprene and is coming in now, with the license agreement, to be a part of the development process. This is the largest and possibly the only development stage deal in the category. We see this as validating for Ovaprene and Daré,” he explained.Given that Grand View Research estimates the contraceptive market could reach up to $11.6 billion by 2025, there is a significant opportunity. Noting that Bayer is already one of the largest players in the women’s health space, McCarthy stated, “The addition of Ovaprene is expected to expand the company’s contraceptive pipeline as the first and only non-hormonal vaginal ring product offered to women.”With this in mind, McCarthy left both his Buy rating and $3 price target as is. This conveys the analyst’s confidence in Daré’s ability to soar 94% over the next twelve months. (To watch McCarthy’s track record, click here)According to the consensus breakdown, McCarthy is the only analyst that has reviewed the stock in the last three months. To this end, the consensus rating is a Moderate Buy and the average price target matches that of McCarthy’s. However, given its impressive recent climb, more analyst ratings could be on the way.To find good ideas for healthcare stocks with solid upside potential, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Incyte's Application for Pemigatinib Gets EMA's Validation
    Zacks

    Incyte's Application for Pemigatinib Gets EMA's Validation

    The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.

  • What Makes Agios Pharmaceuticals (AGIO) a New Buy Stock
    Zacks

    What Makes Agios Pharmaceuticals (AGIO) a New Buy Stock

    Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020

    CAMBRIDGE, Mass., Dec. 23, 2019 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.

  • Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS
    Zacks

    Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS

    The FDA bestows a Breakthrough Therapy status on Agios' (AGIO) leukemia drug Tibsovo for treating relapsed/refractory myelodysplastic syndrome in adult patients with a susceptible IDH1 mutation.

  • Benzinga

    The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...

  • GlobeNewswire

    Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation

    CAMBRIDGE, Mass., Dec. 16, 2019 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.

  • These Hedge Funds Cashed Out Of Agios Pharmaceuticals Inc (AGIO) Too Early
    Insider Monkey

    These Hedge Funds Cashed Out Of Agios Pharmaceuticals Inc (AGIO) Too Early

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]

  • Thomson Reuters StreetEvents

    Edited Transcript of AGIO earnings conference call or presentation 14-Feb-18 1:00pm GMT

    Q4 2017 Agios Pharmaceuticals Inc Earnings Call

  • Here Are The Winners From The Year's Biggest Hematology Meeting
    Investor's Business Daily

    Here Are The Winners From The Year's Biggest Hematology Meeting

    Shares of biotech companies rocketed Monday, led by Forty Seven and Fate, after bullish presentations for cancer and blood-disease drugs at the American Society of Hematology meeting.

  • GlobeNewswire

    Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today reported new data from the extension phase of the DRIVE PK Phase 2 study of mitapivat (AG-348) in adults with pyruvate kinase (PK) deficiency at the 2019 American Society of Hematology (ASH) Annual Meeting. Mitapivat is an investigational, first-in-class, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase-R (PKR) enzymes that directly targets the underlying metabolic defect in PK deficiency, a rare, potentially debilitating, hemolytic anemia.

  • GlobeNewswire

    Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)

    – Combination Therapy with TIBSOVO® and Azacitidine Results in Deep and Durable Molecular Remission in Newly Diagnosed IDH1 Mutant AML – – Mechanisms of Resistance and Relapse.

  • GlobeNewswire

    Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that clinical proof-of-concept has been established based on a preliminary analysis of the Phase 2 trial of mitapivat (AG-348) in patients with non-transfusion-dependent thalassemia. Mitapivat is an investigational, first-in-class, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase-R (PKR) enzymes.

  • GlobeNewswire

    Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of Bruce Car, Ph.D., as chief scientific officer effective January 6, 2020. Dr. Car will replace Scott Biller, Ph.D., who will retire at the end of 2019 and remain a strategic advisor to Agios through 2020 as previously announced.

  • Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag
    Zacks

    Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag

    The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.

  • GlobeNewswire

    Agios Appoints Jonathan Biller as Chief Legal Officer

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of Jonathan Biller to the newly created role of chief legal officer effective December 3, 2019.

  • GlobeNewswire

    Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma

    – Preliminary Efficacy Data Show 31% Overall Response Rate for Both Vorasidenib and TIBSOVO® with Postoperative Treatment – – Vorasidenib and TIBSOVO® Showed 2-HG Suppression.